Clinical trials: Coagulation Protein Disorders
Congenital Bleeding Disorder, Haemophilia B
Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.
- Trial name
- paradigm™6 (NCT02141074)
- Testing
- nonacog beta pegol
- Where
- 93 sites in United States, Algeria and 22 more
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Severe Haemophilia A
Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A
To compare the number of breakthrough bleeds under tailored prophylaxis with Human cell line recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients who received Human-cl rhFVIII as on demand…
- Trial name
- NCT01863758
- Testing
- Human-cl rhFVIII
- Where
- 20 sites in Austria, Bulgaria and 6 more
- Volunteers
- 66 people
- Sponsor
- Octapharma
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Congenital Hemophilia A
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose…
- Trial name
- NCT06738485
- Testing
- Recombinant single-chain factor VIII (rVIII-SingleChain)
- Where
- 20 sites in China
- Volunteers
- 62 people
- Sponsor
- CSL Behring
Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor
Pharmacokinetic-guided Dosing of Emicizumab
The goal of this multicentre, prospective, open-label, cross-over clinical study is to determine whether individualized PK-guided dosing of emicizumab is non-inferior to conventional dosing of emicizumab in the prevention of…
- Conditions
- Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor, Hemophilia A, Severe, Adolescent
- Trial name
- DosEmi (NCT06320626)
- Testing
- Emicizumab - PK-guided dose reduction, Emicizumab - Dosis continuation group, Emicizumab - Dose adjustment group
- Where
- 8 sites in Netherlands
- Volunteers
- 95 people
- Sponsor
- Kathelijn Fischer
Hemophilia A
A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection
Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection (FRSW107) Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and…
- Trial name
- NCT05251090
- Testing
- ADVATE, FRSW107
- Where
- 6 sites in China
- Volunteers
- 13 people
- Sponsor
- Hangzhou Gensciences Biopharmaceutical Co., Ltd.
Factor XI Deficiency, Factor XII Deficiency
The Proteins of the Contact Activation System
Cardiovascular diseases are important causes of morbidity and mortality in the industrialized world. Abnormalities in the coagulation system, causing a hypercoagulable state, are a known risk factor for arterial and venous…
- Trial name
- CONTACT (NCT02785718)
- Testing
- Global Haemostasis assays
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Hemophilia A
Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast
Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast
- Trial name
- NCT05279924
- Testing
- Prophylaxis with Emicizumab
- Where
- Côte d’Ivoire
- Volunteers
- 33 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Influenza Vaccine in Preventing Flu in Patients Who Have Undergone Stem Cell Transplant and in Healthy Volunteers
RATIONALE: The influenza vaccine may help prevent flu in patients who have undergone stem cell transplant. PURPOSE: This clinical trial is studying how well the influenza vaccine works in preventing flu in patients who have…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00952185
- Testing
- cytology specimen collection procedure, fluorescent antibody technique, assessment of therapy complications
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Antithrombin III Deficiency
Atenativ Effect on Uterine Blood Flow and Preeclampsia
The study will be an open controlled pilot study of 6 patients with early-onset severe preeclampsia. Patients will receive Atenativ in addition to conventional therapy The patients will be followed up within the study until three…
- Trial name
- NCT02278575
- Testing
- Atenativ
- Where
- Sweden
- Sponsor
- Vastra Gotaland Region
Hemophilia A
A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate
The main aims of the study are to assess the safety profile of Adynovate as well as how well people respond to the preventive treatment with Adynovate.
- Trial name
- NCT04876365
- Testing
- Non-Interventional
- Where
- Canada
- Volunteers
- 153 people
- Sponsor
- Takeda
Congenital Bleeding Disorder, Haemophilia A
A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of rFVIIa…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B
- Trial name
- NCT01949792
- Testing
- eptacog alfa (activated)
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Novo Nordisk A/S
Hemophilia
Feasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia
In the course of a cross-over study design, 12 patients with hemophilic arthropathy will perform a training load on the knee extensor muscles.
- Trial name
- NCT07259356
- Testing
- Control, BFR Exercise (50% of the LOP) while Leg Press Exercise (4 Sets, All out)
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- University Hospital, Bonn
Haemophilia A
Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
The purpose of this study is to assess the safety and effectiveness of Esperoct® for long-term routine use in patients with Haemophilia A. Participants will get Esperoct® as prescribed by their doctor.
- Trial name
- NCT04334057
- Testing
- Turoctocog alfa pegol
- Where
- 20 sites in Japan
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial
RATIONALE: Providing information that is tailored to answer patients' questions about clinical trials may help patients with cancer decide to enroll in a clinical trial.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00750009
- Testing
- educational intervention
- Where
- 4 sites in United States
- Volunteers
- 583 people
- Sponsor
- Case Comprehensive Cancer Center
Haemophilia, Autism Spectrum Disorder
Prevalence of Autistic Spectrum Disorder (ASD) in Children With Haemophilia
Parents of children with haemophilia will be invited to complete 3 questionnaires to look for traits present in ASD. With consent teacher will complete a further 2 questionnaires.
- Conditions
- Haemophilia, Autism Spectrum Disorder, Social Communication Disorder, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05138224
- Volunteers
- 82 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Hemophilia A, Hemophilia B
Data Registry in Chinese Hemophilia A and B Patients
This is an open-label, prospective, multi-center, patient registry in Chinese Hemophilia A and B patients treated with anti-hemophilic coagulation factor replacement therapy.
- Trial name
- NCT07101224
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors, 12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk…
- Trial name
- NCT04647227
- Testing
- coagulation factor VIIa [recombinant]-jncw
- Where
- 21 sites in United States
- Volunteers
- 55 people
- Sponsor
- American Thrombosis and Hemostasis Network
Hemophilia A
International PMS Study - KOGENATE Bayer
To evaluate long-term safety (primarily by recording adverse events including inhibitors), efficacy and patient acceptance of KOGENATE Bayer in home treatment either on prophylaxis or on demand.
- Trial name
- NCT00864552
- Testing
- Kogenate (BAY14-2222)
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 200 people
- Sponsor
- Bayer
Idiopathic Thrombocytopenic Purpura, Thrombocytopenia
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety…
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura
- Trial name
- NCT00415532
- Testing
- Medical Standard of Care for ITP, Romiplostim
- Volunteers
- 234 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.